

References

I-36

1. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: Antiemesis. Version. 1.2019.
2. Sadaba B, Barrio A, Campanero M, et al. Randomized pharmacokinetic study comparing subcutaneous and intravenous palonosetron in cancer patients treated with platinum based chemotherapy. *PlosOne*. February 2014;9(2):e89747.
3. Candiotti K, Ahmed S, Cox D, et al. Palonosetron versus ondansetron as rescue medication for postoperative nausea and vomiting: a randomized, multicenter, open-label study. *BMC Pharmacology and Toxicology*. 2014;15:45.
4. Aloxi ® (palonosetron HCl) injection for intravenous use [package insert]. Helsinn Therapeutics, Inc. Iselin, NJ. Revised 09/2018.
5. Gilmore J, Peacock N, Gu A, et al. Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE study. *Journal of Oncology Practice*. January 2014; 10(1):68-74.
6. P Hesketh, K Bohlke, G Lyman. Antiemetics: American Society of Clinical Oncology Focused Guideline Update. *Journal of Clinical Oncology*. November 2015.64.3635.
7. MICROMEDEX®SOLUTIONS Compendia. 2019. Palonosetron.
8. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Palonosetron. 2019.
9. NCCN Drugs & Biologics Compendium™. Palonosetron. 2019. National Comprehensive Cancer Network (NCCN).
10. Delaware State Mandate; 18 DE Code, §§3338B and 3555B.
11. Bungo Saito, Hidetoshi Nakashima, Maasa Abe, et al. Efficacy of palonosetron to prevent delayed nausea and vomiting in non-Hodgkin's lymphoma patients undergoing repeated cycles of the CHOP regimen. *Supportive Care in Cancer*. 2018;26(1):269-274.
12. van der Vorst MJDL, Neefjes ECW, Konings IRHM, Verheul HMW. Prophylactic treatment for delayed chemotherapy-induced nausea and vomiting after non-AC based moderately emetogenic chemotherapy: a systematic review of randomized controlled trials. *Supportive Care in Cancer*. 2015;23(8):2499-2506
13. Mukhopadhyay S, Kwatra G, Alice K P, Badyal D. Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study. *Supportive Care in Cancer*. 2017;25(1):145-154.
14. Hayashi T, Shimokawa M, Miyoshi T, et al. A prospective, observational, multicenter study on risk factors and prophylaxis for low emetic risk chemotherapy-induced nausea and vomiting. *Supportive Care in Cancer*. 2017;25(9):2707-2714.